Printer Friendly

Corgentech announces patent issuance for E2F transcription factor decoy technology.

Corgentech, Inc. (South San Francisco, CA) a biotechnology company, announced that the United States Patent and Trademark Office has issued United States Patent 6,774,118. The patent covers a method for preventing formation of neointimal thickening leading to restenosis and vessel occlusion with any double-stranded oligonucleotide decoy that binds to the transcription factor, E2F, regardless of the sequence of such decoy. The patent is assigned to Brigham and Women's Hospital (Boston, MA), and is exclusively licensed to Corgentech. E2F is a transcription factor family that is responsible for the activation of genes involved in the growth and proliferation of the smooth muscle cells that can lead to neointimal hyperplasia, plaque build-up, venous graft failure or restenosis.

"We are very pleased by the issuance of the latest, and one of the most fundamental, United States patents protecting our E2F Decoy technology," said John P. McLaughlin, Corgentech's president and chief executive officer. "United States Patent 6,774,118 further solidifies our intellectual property position as we move toward commercial development of our lead product candidate."

In October 2003, Corgentech, Inc. and Bristol-Myers Squibb Company entered into an agreement to jointly develop and commercialize Corgentech's edifoligide (E2F Decoy), a first-of-its-kind treatment currently in Phase III development for the prevention of vein graft failure following coronary artery bypass graft and peripheral artery (i.e., leg) bypass graft surgery.

Corgentech is a biopharmaceutical company engaged in the discovery, development and commercialization of a new class of therapeutics called transcription factor decoys, or TF decoys. We are creating a pipeline of novel therapeutics based on our proprietary TF decoy technology, focused initially on the treatment of cardiovascular disease, inflammatory disease, such as arthritis and dermatitis, and cancer.

Corgentech, Inc.

+1-650-624-9600

www.corgentech.com
COPYRIGHT 2004 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:Corgentech announces patent issuance for E2F transcription factor decoy technology.
Publication:BIOTECH Patent News
Article Type:Brief Article
Geographic Code:1USA
Date:Aug 1, 2004
Words:288
Previous Article:Lexicon extends intellectual property portfolio with patent on gene trapping.
Next Article:GMP obtains two patents involving bag proteins and nucleic acid molecules encoding them and porous biodegradable polymeric materials for cell...
Topics:


Related Articles
Nippon Paper obtains United States patent.
Sangamo BioSciences granted patent covering methods for identifying target sequences.
Sangamo BioSciences granted zinc finger DNA-binding protein patent.
Amnis granted eight U.S. patents for high speed cell analysis platform.
Corgentech licenses peptide delivery system from Cyclacel.
Sirna Therapeutics obtains patents covering siRNAs targeting VEGF and HCV.
Microarrays and transcription networks.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters